The future of the generics landscape: Key branded drugs losing exclusivity in 2021 and beyond

Clarivate, a global leader in providing trusted information and insights to accelerate the pace of innovation, announced the launch of its new report identifying six branded drugs to watch that are losing exclusivity in 2021 and beyond that could impact the generics market. The report also flags the antineoplastics therapeutic area, which has several brands expected to lose exclusivity in the next five years.

Patent expirations in specialty drugs and biologics offer potentially substantial cost savings to patients and payers. Generics comprise the majority of prescriptions in the world’s top market places. Their share is only likely to grow, with biosimilars beginning to make a serious impact.

Generic drugs now account for 92% of all prescription drugs dispensed in the United States, according to figures from the International Generics and Biosimilar Medicines Association.

In Europe, 67% of drugs dispensed are generic, and in Japan, generics make up 77% of prescription drugs by volume.

Over the next seven years, there are at least 120 molecules that are predicted to lose exclusivity annually in key global markets. These all have the potential to be genericised and contribute to more affordable health care for patients globally.

A post-pandemic world needs more affordable alternatives and stronger supply chains Generics and biosimilars are poised to play a key role in meeting patient needs as the world’s economies and health systems recover. The generics and biosimilars ecosystem is expected to grow larger and more diverse over the next few years, shaped by financial pressures on payers and manufacturers alike.

Top three brands losing exclusivity in key markets in 2021

Although there are a number of products losing exclusivity in 2021, many countries will see a sharp increase in 2022. An ability to forecast which drugs will be impacted helps pharma companies plan accordingly and highlights opportunities for manufacturers.

The top three brands that are expected to lose exclusivity in 2021 in each market according to global sales reported in Cortellis Generics Intelligence by molecule (Jan 1, 2020 to Dec 31, 2020) are:

United States: BROVANA, JUBLIA and VOTRIENT

Europe (top five countries): CIMZIA, ESBRIET and NEXAVAR

Japan: VEMLIDY, ALLERMIST and XEPLION

Download the full report now to learn more about their potential impact on the future of the generics market.

About Clarivate

Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world’s most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialise their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.